Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy

Nature Reviews Immunology

Volumn 13, Issue 12, 2013, Pages 862-874

  Hotchkiss, Richard S ^a   Monneret, Guillaume ^b   Payen, Didier ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; ANTIBODY; CHEMOKINE RECEPTOR CXCR2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTOXIN; FLT3 LIGAND; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 7 RECEPTOR; L SELECTIN; LIPOPOLYSACCHARIDE; PHARMACOLOGICAL BIOMARKER; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 17; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; B LYMPHOCYTE; BACTEREMIA; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CLONAL ANERGY; CRYPTOCOCCAL MENINGITIS; CYTOKINE PRODUCTION; DENDRITIC CELL; EXTRACORPOREAL CELL THERAPY; EXTRACORPOREAL CIRCULATION; FOLLICULAR DENDRITIC CELL; FUNGEMIA; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOSENESCENCE; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; INTENSIVE CARE; INTESTINE LYMPHATIC TISSUE; LYMPH NODE; LYMPHOCYTOPENIA; MACROPHAGE; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PERITONITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; SPLEEN; SUPPRESSOR CELL; TH1 CELL; TH17 CELL; TH2 CELL; THEORY; THYMUS;

ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOTHERAPY; INFLAMMATION; MICE; MODELS, ANIMAL; SEPSIS;

EID: 84888325490     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3552     Document Type: Review

References (170)

1. Vincent, J. L., Opal, S. M., Marshall, J. C. & Tracey, K. J. Sepsis definitions: time for change. Lancet 381, 774-775 (2013).
2. Martin, G. S., Mannino, D. M. & Moss, M. The effect of age on the development and outcome of adult sepsis. Crit. Care Med. 34, 15-21 (2006). (Pubitemid 43032375)
3. Cohen, J., Opal, S. & Calandra, T. Sepsis studies need new direction. Lancet Infect. Dis. 12, 503-505 (2012).
4. Wenzel, R. P. & Edmond, M. B. Septic shock-evaluating another failed treatment. N. Engl. J. Med. 366, 2122-2124 (2012).
5. Ward, P. A. New approaches to the study of sepsis. EMBO Mol. Med. 4, 1234-1243 (2012).
6. Angus, D. C. The search for effective therapy for sepsis: back to the drawing board JAMA 306, 2614-2615 (2011).
7. Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260-268 (2013).
8. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003). (Pubitemid 36056721)
9. Hotchkiss, R. S. & Opal, S. Immunotherapy for sepsis-a new approach against an ancient foe. N. Engl. J. Med. 363, 87-89 (2010).
10. Payen, D., Monneret, G. & Hotchkiss, R. Immunotherapy-a potential new way forward in the treatment of sepsis. Crit. Care 17, 118 (2013).
11. Hall, M. W. et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37, 525-532 (2011).
12. Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594-2605 (2011).
13. Ward, P. A. Immunosuppression in sepsis. JAMA 306, 2618-2619 (2011).
14. Torgersen, C. et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth. Analg. 108, 1841-1847 (2009).
15. Otto, G. P. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 (2011).
16. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
17. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
18. Munford, R. S. & Pugin, J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 163, 316-321 (2001). (Pubitemid 32158505)
19. Xiao, W. et al. A genomic storm in critically injured humans. J. Exp. Med. 208, 2581-2590 (2011).
20. Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S. & Remick, D. G. The pathogenesis of sepsis. Annu. Rev. Pathol. 6, 19-48 (2011).
21. Geiger, H., de Haan, G. & Florian, M. C. The ageing haematopoietic stem cell compartment. Nature Rev. Immunol. 13, 376-389 (2013).
22. van Dissel, J. T., van Langevelde, P., Westendorp, R. G., Kwappenberg, K. & Frölich, M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351, 950-953 (1998). (Pubitemid 28138469)
23. Ertel, W. et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85, 1341-1347 (1995).
24. Munoz, C. et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88, 1747-1754 (1991).
25. Rigato, O. & Salomao, R. Impaired production of interferon-and tumor necrosis factor-but not of interleukin 10 in whole blood of patients with sepsis. Shock 19, 113-116 (2003).
26. Wong, H. R. Genome-wide expression profiling in pediatric septic shock. Pediatr. Res. 73, 564-569 (2013).
27. Hotchkiss, R. S. et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27, 1230-1251 (1999). (Pubitemid 29379358)
28. Hotchkiss, R. S. et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166, 6952-6963 (2001). (Pubitemid 32467243)
29. Hotchkiss, R. S. et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 168, 2493-2500 (2002). (Pubitemid 34171855)
30. Felmet, K. A., Hall, M. W., Clark, R. S., Jaffe, R. & Carcillo, J. A. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J. Immunol. 174, 3765-3772 (2005). (Pubitemid 40354089)
31. Toti, P. et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am. J. Clin. Pathol. 122, 765-771 (2004). (Pubitemid 39434758)
32. Hotchkiss, R. S. et al. Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock. Crit. Care Med. 28, 3207-3217 (2000).
33. Chang, K. C. et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J. 21, 708-719 (2007). (Pubitemid 46348247)
34. Hotchkiss, R. S. et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J. Immunol. 162, 4148-4156 (1999). (Pubitemid 29314800)
35. Chung, C. S. et al. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J. Leukoc. Biol. 74, 344-351 (2003).
36. Oberholzer, C. et al. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc. Natl Acad. Sci. USA 98, 11503-11508 (2001). (Pubitemid 32928758)
37. Iwata, A. et al. Over-expression of Bcl-2 provides protection in septic mice by a trans effect. J. Immunol. 171, 3136-3141 (2003). (Pubitemid 37093537)
38. Voll, R. E. et al. Immunosuppressive effects of apoptotic cells. Nature 390, 350-351 (1997).
39. Green, D. R. & Beere, H. M. Apoptosis. Gone but not forgotten. Nature 405, 28-29 (2000).
40. Tamayo, E. et al. Evolution of neutrophil apoptosis in septic shock survivors and nonsurvivors. J. Crit. Care 27, 415.e1-415.e11 (2012).
41. Drifte, G., Dunn-Siegrist, I., Tissieres, P. & Pugin, J. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit. Care Med. 41, 820-832 (2013).
42. Alves-Filho, J. C., Spiller, F. & Cunha, F. Q. Neutrophil paralysis in sepsis. Shock 34 (Suppl. 1), 15-21 (2010).
43. Kovach, M. A. & Standiford, T. J. The function of neutrophils in sepsis. Curr. Opin. Infect. Dis. 25, 321-327 (2012).
44. Cummings, C. J. et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J. Immunol. 162, 2341-2346 (1999). (Pubitemid 29288860)
45. Stephan, F. et al. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit. Care Med. 30, 315-322 (2002). (Pubitemid 34158113)
46. Delano, M. J. et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J. Immunol. 186, 195-202 (2011).
47. Altrichter, J. et al. Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study. Crit. Care 15, R82 (2011).
48. Kasten, K. R., Muenzer, J. T. & Caldwell, C. C. Neutrophils are significant producers of IL-10 during sepsis. Biochem. Biophys. Res. Commun. 393, 28-31 (2010).
49. Pillay, J. et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J. Clin. Invest. 122, 327-336 (2012).
50. Delano, M. J. et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204, 1463-1474 (2007). (Pubitemid 46919883)
51. Makarenkova, V. P., Bansal, V., Matta, B. M., Perez, L. A. & Ochoa, J. B. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176, 2085-2094 (2006). (Pubitemid 43201655)
52. Cuenca, A. G. et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17, 281-292 (2011).
53. Brudecki, L., Ferguson, D. A., McCall, C. E. & El Gazzar, M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect. Immun. 80, 2026-2034 (2012).
54. Dumitru, C. A., Moses, K., Trellakis, S., Lang, S. & Brandau, S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61, 1155-1167 (2012).
55. Guisset, O. et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med. 33, 148-152 (2007). (Pubitemid 46115483)
56. Riccardi, F. et al. Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. Cytometry B Clin. Cytom. 80, 14-21 (2011).
57. Poehlmann, H., Schefold, J. C., Zuckermann-Becker, H., Volk, H. D. & Meisel, C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit. Care 13, R119 (2009).
58. Dreschler, K. et al. Altered phenotype of blood dendritic cells in patients with acute pneumonia. Respiration 83, 209-217 (2012).
59. Grimaldi, D. et al. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med. 37, 1438-1446 (2011).
60. Pastille, E. et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J. Immunol. 186, 977-986 (2011).
61. Faivre, V. et al. Human monocytes differentiate into dendritic cells subsets that induce anergic and regulatory T cells in sepsis. PLoS ONE 7, e47209 (2012).
62. Gautier, E. L. et al. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immuno-suppression and increases resistance to lethal endotoxic shock. J. Immunol. 180, 6941-6946 (2008).
63. Bohannon, J., Cui, W., Sherwood, E. & Toliver-Kinsky, T. Dendritic cell modification of neutrophil responses to infection after burn injury. J. Immunol. 185, 2847-2853 (2010).
64. Toliver-Kinsky, T. E., Cui, W., Murphey, E. D., Lin, C. & Sherwood, E. R. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. J. Immunol. 174, 404-410 (2005). (Pubitemid 40007428)
65. Toliver-Kinsky, T. E., Lin, C. Y., Herndon, D. N. & Sherwood, E. R. Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice. Infect. Immun. 71, 3058-3067 (2003). (Pubitemid 36637527)
66. Benjamim, C. F., Hogaboam, C. M., Lukacs, N. W. & Kunkel, S. L. Septic mice are susceptible to pulmonary aspergillosis. Am. J. Pathol. 163, 2605-2617 (2003). (Pubitemid 37466501)
67. Benjamim, C. F., Lundy, S. K., Lukacs, N. W., Hogaboam, C. M. & Kunkel, S. L. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 105, 3588-3595 (2005). (Pubitemid 40628205)
68. Roquilly, A. et al. TLR-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur. Respir. J. http://dx.doi.org/10.1183/ 09031936.00152612 (2013).
69. Scumpia, P. O. et al. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J. Immunol. 175, 3282-3286 (2005). (Pubitemid 41170549)
70. Cavaillon, J. M. & Adib-Conquy, M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 10, 233 (2006).
71. Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475-487 (2009).
72. Zhang, X. & Morrison, D. C. Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages. J. Leukoc. Biol. 54, 444-450 (1993). (Pubitemid 23347844)
73. Monneret, G. et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32, 1175-1183 (2006). (Pubitemid 44232412)
74. Rossato, M. et al. IL-10-induced microRNA-187 negatively regulates TNF-, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc. Natl Acad. Sci. USA 109, E3101-E3110 (2012).
75. Ishii, M. et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114, 3244-3254 (2009).
76. Carson, W. F., Cavassani, K. A., Dou, Y. & Kunkel, S. L. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 6, 273-283 (2011).
77. Turrel-Davin, F. et al. mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Crit. Care 15, R252 (2011).
78. Chen, J. & Ivashkiv, L. B. IFN-abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc. Natl Acad. Sci. USA 107, 19438-19443 (2010).
79. Monneret, G. et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol. Lett. 95, 193-198 (2004). (Pubitemid 39237665)
80. Gogos, C. A., Drosou, E., Bassaris, H. P. & Skoutelis, A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181, 176-180 (2000). (Pubitemid 30049046)
81. Hynninen, M. et al. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and-10 levels in critically ill patients with sepsis. Shock 20, 1-4 (2003).
82. Oberholzer, A., Oberholzer, C. & Moldawer, L. L. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit. Care Med. 30, S58-S63 (2002). (Pubitemid 34131163)
83. Sfeir, T., Saha, D. C., Astiz, M. & Rackow, E. C. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit. Care Med. 29, 129-133 (2001). (Pubitemid 32125786)
84. Muehlstedt, S. G., Lyte, M. & Rodriguez, J. L. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock 17, 443-450 (2002).
85. Randow, F. et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor . J. Exp. Med. 181, 1887-1892 (1995).
86. Muenzer, J. T. et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun. 78, 1582-1592 (2010).
87. Lukaszewicz, A. C. et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Med. 37, 2746-2752 (2009).
88. Astiz, M., Saha, D., Lustbader, D., Lin, R. & Rackow, E. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J. Lab Clin. Med. 128, 594-600 (1996). (Pubitemid 27506766)
89. Rode, H. N. et al. Lymphocyte function in anergic patients. Clin. Exp. Immunol. 47, 155-161 (1982). (Pubitemid 12251294)
90. Monneret, G., Venet, F., Pachot, A. & Lepape, A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol. Med. 14, 64-78 (2008). (Pubitemid 351356886)
91. Venet, A., Lukaszewica, A., Payen, D., Hotchkiss, R. & Monneret, G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr. Opin. Immunol. 25, 477-483 (2013).
92. Landelle, C. et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 36, 1859-1866 (2010).
93. Chiche, L. et al. The role of natural killer cells in sepsis. J. Biomed. Biotechnol. 2011, 986491 (2011).
94. Souza-Fonseca-Guimaraes, F., Adib-Conquy, M. & Cavaillon, J. M. Natural killer (NK) cells in antibacterial innate immunity: angels or devils Mol. Med. 18, 270-285 (2012).
95. Venet, F. et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 34, 358-363 (2010).
96. Forel, J. M. et al. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS ONE 7, e50446 (2012).
97. Holub, M. et al. Lymphocyte subset numbers depend on the bacterial origin of sepsis. Clin. Microbiol. Infect. 9, 202-211 (2003). (Pubitemid 36511679)
98. Giamarellos-Bourboulis, E. J. et al. Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit. Care 10, R166 (2006).
99. Souza-Fonseca-Guimaraes, F. et al. Toll-like receptors expression and interferon-production by NK cells in human sepsis. Crit. Care 16, R206 (2012).
100. Puente, J. et al. In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with-interferon and interleukin-2. Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 271-275 (1993). (Pubitemid 23187443)
101. Georgeson, G. D. et al. Natural killer cell cytotoxicity is deficient in newborns with sepsis and recurrent infections. Eur. J. Pediatr. 160, 478-482 (2001). (Pubitemid 32695827)
102. Blazar, B. A. et al. Suppression of natural killer-cell function in humans following thermal and traumatic injury. J. Clin. Immunol. 6, 26-36 (1986). (Pubitemid 16128506)
103. Bender, B. S. et al. Depressed natural killer cell function in thermally injured adults: successful in vivo and in vitro immunomodulation and the role of endotoxin. Clin. Exp. Immunol. 71, 120-125 (1988). (Pubitemid 18047711)
104. Chiche, L. et al. Interferon-production by natural killer cells and cytomegalovirus in critically ill patients. Crit. Care Med. 40, 3162-3169 (2012).
105. Souza-Fonseca-Guimaraes, F., Parlato, M., Fitting, C., Cavaillon, J. M. & Adib-Conquy, M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J. Immunol. 188, 5850-5858 (2012).
106. Luyt, C. E. et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am. J. Respir. Crit. Care Med. 175, 935-942 (2007).
107. Limaye, A. P. et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300, 413-422 (2008). (Pubitemid 352040253)
108. Cook, C. H. & Trgovcich, J. Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. Antiviral Res. 90, 151-159 (2011).
109. Chiche, L., Forel, J. M. & Papazian, L. The role of viruses in nosocomial pneumonia. Curr. Opin. Infect. Dis. 24, 152-156 (2011).
110. Wesselkamper, S. C. et al. NKG2D is critical for NK cell activation in host defense against Pseudomonas aeruginosa respiratory infection. J. Immunol. 181, 5481-5489 (2008).
111. Vantourout, P. & Hayday, A. Six-of-the-best:unique contributions of T cells to immunology. Nature Rev. Immunol. 13, 88-100 (2013).
112. Andreu-Ballester, J. C. et al. Association of T cells with disease severity and mortality in septic patients. Clin. Vaccine Immunol. 20, 738-746 (2012).
113. Hotchkiss, R. S. et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 174, 5110-5118 (2005).
114. Gouel-Cheron, A., Venet, F., Allaouchiche, B. & Monneret, G. CD4+ T-lymphocyte alterations in trauma patients. Crit. Care 16, 432 (2012).
115. Le Tulzo, Y. et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 18, 487-494 (2002).
116. Inoue, S. et al. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit. Care Med. 41, 810-819 (2013).
117. Heffernan, D. S. et al. Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern. Crit. Care 16, R12 (2012).
118. Cheadle, W. G. et al. Lymphocyte subset responses to trauma and sepsis. J. Trauma 35, 844-849 (1993). (Pubitemid 24018481)
119. Venet, F. et al. Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25-lymphocytes. Crit. Care Med. 32, 2329-2331 (2004). (Pubitemid 39491817)
120. De, A. K. et al. Induction of global anergy rather than inhibitory Th2 lymphokines mediates posttrauma T cell immunodepression. Clin. Immunol. 96, 52-66 (2000). (Pubitemid 30447930)
121. Heidecke, C. D. et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am. J. Surg. 178, 288-292 (1999).
122. Wick, M., Kollig, E., Muhr, G. & Koller, M. The potential pattern of circulating lymphocytes TH1/TH2 is not altered after multiple injuries. Arch. Surg. 135, 1309-1314 (2000).
123. Pachot, A. et al. Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin. Immunol. 114, 61-69 (2005). (Pubitemid 39642791)
124. Venet, F. et al. Regulatory T cell populations in sepsis and trauma. J. Leukoc. Biol. 83, 523-535 (2008). (Pubitemid 351966861)
125. Carson, W. F.t. et al. Impaired CD4+ T-cell proliferation and effector function correlates with repressive histone methylation events in a mouse model of severe sepsis. Eur. J. Immunol. 40, 998-1010 (2010).
126. Romani, L. Immunity to fungal infections. Nature Rev. Immunol. 11, 275-288 (2011).
127. Gow, N. A., van de Veerdonk, F. L., Brown, A. J. & Netea, M. G. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nature Rev. Microbiol. 10, 112-122 (2011).
128. van de Veerdonk, F. L. et al. Deficient Candida-specific T-helper 17 response during sepsis. J. Infect. Dis. 206, 1798-1802 (2012).
129. Monneret, G., Venet, F., Kullberg, B. J. & Netea, M. G. ICU-acquired immunosuppression and the risk for secondary fungal infections. Med. Mycol. 49 (Suppl. 1), S17-23 (2011).
130. Unsinger, J. et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J. Infect. Dis. 206, 606-616 (2012).
131. Kasten, K. R. et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through T-cell IL-17 production in a murine model of sepsis. Infect. Immun. 78, 4714-4722 (2010).
132. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998). (Pubitemid 29028493)
133. Wherry, E. J. T cell exhaustion. Nature Immunol. 12, 492-499 (2011).
134. Guignant, C. et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care 15, R99 (2011).
135. Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303-6308 (2009).
136. Brahmamdam, P. et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol. 88, 233-240 (2010).
137. Zhang, Y. et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit. Care 14, R220 (2010).
138. Monneret, G. et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit. Care Med. 31, 2068-2071 (2003). (Pubitemid 36900766)
139. Zanin-Zhorov, A. et al. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J. Clin. Invest. 116, 2022-2032 (2006). (Pubitemid 44033326)
140. Huang, L. F. et al. Association between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study. Crit. Care 14, R3 (2010).
141. Venet, F. et al. Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 35, 678-686 (2009).
142. Carrigan, S. O. et al. Depletion of natural CD4+CD25+ T regulatory cells with anti-CD25 antibody does not change the course of Pseudomonas aeruginosa-induced acute lung infection in mice. Immunobiology 214, 211-222 (2009).
143. Scumpia, P. O. et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood 110, 3673-3681 (2007). (Pubitemid 350159636)
144. Cavassani, K. A. et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 115, 4403-4411 (2010).
145. Venet, F. et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177, 6540-6547 (2006). (Pubitemid 44628873)
146. Li, L. & Wu, C. Y. CD4+ CD25+ Treg cells inhibit human memory T cells to produce IFN-in response to M tuberculosis antigen ESAT-6. Blood 111, 5629-5636 (2008).
147. Tiemessen, M. M. et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl Acad. Sci. USA 104, 19446-19451 (2007).
148. Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nature Rev. Immunol. 11, 330-342 (2011).
149. Perales, M. A. et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 120, 4882-4891 (2012).
150. Unsinger, J. et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 184, 3768-3779 (2010).
151. Venet, F. et al. Decreased T-cell repertoire diversity in sepsis: a preliminary study. Crit. Care Med. 41, 111-119 (2013).
152. Levy, Y. et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a Phase I/IIa randomized, placebo-controlled, multicenter study. Clin. Infect. Dis. 55, 291-300 (2012).
153. Pellegrini, M. et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 144, 601-613 (2011).
154. Venet, F. et al. IL-7 restores lymphocyte functions in septic patients. J. Immunol. 189, 5073-5081 (2012).
155. Chang, K. C. et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit. Care 17, R85 (2013).
156. Singh, A., Mohan, A., Dey, A. B. & Mitra, D. K. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon-producing T cells from apoptosis in patients with pulmonary tuberculosis. J. Infect. Dis. 208, 603-615 (2013).
157. Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-treatment. Nature Med. 3, 678-681 (1997).
158. Nalos, M. et al. Immune effects of interferon in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185, 110-112 (2012).
159. Marciano, B. E. et al. Long-term interferon-therapy for patients with chronic granulomatous disease. Clin. Infect. Dis. 39, 692-699 (2004). (Pubitemid 39180442)
160. Jarvis, J. N. et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 26, 1105-1113 (2012).
161. Root, R. K. et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. 31, 367-373 (2003). (Pubitemid 36232927)
162. Nelson, S. et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J. Infect. Dis. 178, 1075-1080 (1998). (Pubitemid 28452201)
163. Meisel, C. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640-648 (2009).
164. Reinhart, K., Bauer, M., Riedemann, N. C. & Hartog, C. S. New approaches to sepsis: molecular diagnostics and biomarkers. Clin. Microbiol. Rev. 25, 609-634 (2012).
165. Leentjens, J., Kox, M., van der Hoeven, J. G., Netea, M. G. & Pickkers, P. Immunotherapy for the adjunctive treatment of sepsis: from immuno-suppression to immunostimulation. Time for a paradigm change Am. J. Respir. Crit. Care Med. 187, 1287-1293 (2013).
166. Wong, H. R. Genetics and genomics in pediatric septic shock. Crit. Care Med. 40, 1618-1626 (2012).
167. Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004). (Pubitemid 38263654)
168. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507-3512 (2013).
169. Brahmamdam, P. et al. Targeted delivery of siRNA to cell death proteins in sepsis. Shock 32, 131-139 (2009).
170. Weber, S. U. et al. Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit. Care 12, R128 (2008).